---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038053"
form_type: "8-K"
ticker: null
cik: "0001850838"
company_name: "Omega Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:34:27.306610+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omega Therapeutics reports FY 2023 net loss $97.4M; cuts headcount 35%, extends cash runway to Q1 2025

## Summary
- Cash, equivalents and marketable securities $73.4M as of Dec. 31, 2023; expected to fund operations into Q1 2025.
- OTX-2002 in HCC showed 80% disease control rate (4/5) in early cohorts; Cohort 5 (0.3 mg/kg) opened in March 2024.
- Novo Nordisk collaboration for obesity: up to $532M in milestones plus tiered royalties; target enhances thermogenesis.
- R&D expense $77.2M in 2023 vs $81.2M in 2022; net loss $97.4M vs $102.7M; headcount reduced ~35%.
- Prioritized programs: OTX-2101 (NSCLC), HNF4A (liver regeneration), obesity controller; expect next clinical data mid-2024.

## SEC filing metadata
- accession: 0000950170-24-038053
- form_type: 8-K
- cik: 0001850838
- company_name: Omega Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/0000950170-24-038053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/omga-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038053
- JSON: https://secwatch.observer/filing/0000950170-24-038053.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038053.txt

## Key facts
- Earnings Releases
  Omega Therapeutics, Inc. reported financial results for for the fourth quarter and full year ended December 31, 2023.
  - Period: for the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Omega Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/0000950170-24-038053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.